Nasdaq

Axonics® Announces U.S. Food & Drug Administration Approval of Wireless Patient Remote Control with SmartMRI Technology

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation ...
Nasdaq

Axonics® Announces Survey Results of Patients Treated with the Axonics r-SNM System That Were Previously Implanted with InterStim II

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation ...
Monthly Prescribing Reference

Sacral Neuromodulation Device Approved for OAB, Urinary Retention

The Axonics r-SNM System includes a neurostimulator, patented tined lead, remote control, and a charging system. The small, neurostimulator is implanted through a minimally invasive outpatient ...
Reuters

Axonics Reports FDA Approval Of Wireless Patient Remote Control With SmartMRI Technology

* AXONICS MODULATION TECHNOLOGIES - FDA REVIEW OF LABELING EXPANSION EXPECTED TO COMPLETE IN EARLY Q4 Source text for Eikon: Further company coverage: ...
The Motley Fool

Medtronic's Bladder-Control Devices Have a Feisty New Competitor

In November, the Food and Drug Administration (FDA) approved r-SNM, the first rechargeable sacral nerve stimulator cleared for full-body MRI scans, and sales results from the initial launch were ...